Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119835) titled 'A Preliminary Study on the Safety and Efficacy of NCK-1512 Cell Therapy in Patients with Advanced Lung Cancer' on March 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The General Hospital of the Eastern Theater Command of the People's Liberation Army of China
Condition:
Advanced Lung Cancer
Intervention:
Group 1:NCK-1512 cells, secreting IL-15 (12.5 ng/kg/day) and IL-12 (30 ng/kg/day), are administered via infusion
Group 2:NCK-1512 cells, secreting IL-15 (37.5 ng/kg/day) and IL-12 (90 ng/kg/day), are administered via infusion
Recruitment Status: Not Recruiting
Phase: N/A ...